MagForce AG operates in the field of nanotechnology-based cancer treatment in Germany and Poland.
Exceptional growth potential and slightly overvalued.
Share Price & News
How has MagForce's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: MGFR.F has not had significant price volatility in the past 3 months.
7 Day Return
US Medical Equipment
1 Year Return
US Medical Equipment
Return vs Industry: Insufficient data to determine how MGFR.F performed against the US Medical Equipment industry.
Return vs Market: Insufficient data to determine how MGFR.F performed against the US Market.
Price Volatility Vs. Market
How volatile is MagForce's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is MagForce undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: MGFR.F ($3.3) is trading below our estimate of fair value ($18.51)
Significantly Below Fair Value: MGFR.F is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: MGFR.F is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.
PE vs Market: MGFR.F is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate MGFR.F's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: MGFR.F is overvalued based on its PB Ratio (4.1x) compared to the US Medical Equipment industry average (2.9x).
How is MagForce forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MGFR.F is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (1.7%).
Earnings vs Market: MGFR.F is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: MGFR.F's is expected to become profitable in the next 3 years.
Revenue vs Market: MGFR.F's revenue (50.9% per year) is forecast to grow faster than the US market (7% per year).
High Growth Revenue: MGFR.F's revenue (50.9% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: MGFR.F's Return on Equity is forecast to be very high in 3 years time (50.8%).
How has MagForce performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: MGFR.F is currently unprofitable.
Growing Profit Margin: MGFR.F is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: MGFR.F is unprofitable, and losses have increased over the past 5 years at a rate of -6.9% per year.
Accelerating Growth: Unable to compare MGFR.F's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: MGFR.F is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (1%).
Return on Equity
High ROE: MGFR.F has a negative Return on Equity (-25.54%), as it is currently unprofitable.
How is MagForce's financial position?
Financial Position Analysis
Short Term Liabilities: MGFR.F's short term assets (€3.8M) exceed its short term liabilities (€3.4M).
Long Term Liabilities: MGFR.F's short term assets (€3.8M) do not cover its long term liabilities (€16.9M).
Debt to Equity History and Analysis
Debt Level: MGFR.F's debt to equity ratio (89.2%) is considered high.
Reducing Debt: Insufficient data to determine if MGFR.F's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Insufficient data to determine if MGFR.F has enough cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if MGFR.F has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is MagForce's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate MGFR.F's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate MGFR.F's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if MGFR.F's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if MGFR.F's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of MGFR.F's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Ben Lipps (79yo)
Dr. Benjamin J. Lipps, also known as Ben, has been the Chairman of the Management Board and Chief Executive Officer at MagForce AG since September 1, 2013. Dr. Lipps served as the Chief Executive Officer a ...
|Chairman of the Management Board & CEO||6.58yrs||no data||no data|
|Founder & Advisor||no data||no data||no data|
|CFO & Member of Management Board||7.5yrs||no data||no data|
|Chief Medical Officer & Member of Management Board||7.5yrs||no data||no data|
|Vice President of Communications & Investor Relations||4.08yrs||no data||no data|
|VP of Marketing & Sales and European Commercial Director||no data||no data||no data|
|Medical Consultant||9.42yrs||no data||no data|
Experienced Management: MGFR.F's management team is seasoned and experienced (7.5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 4.9%.
MagForce AG's company bio, employee growth, exchange listings and data sources
- Name: MagForce AG
- Ticker: MGFR.F
- Exchange: OTCPK
- Founded: 1997
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: €71.865m
- Listing Market Cap: €78.584m
- Shares outstanding: 27.64m
- Website: https://www.magforce.com
Number of Employees
- MagForce AG
- Max-Planck-Strasse 3
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|MF6||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Sep 2007|
|MF6||XTRA (XETRA Trading Platform)||Yes||Common Stock||DE||EUR||Sep 2007|
|MGFR.F||OTCPK (Pink Sheets LLC)||Yes||Common Stock||US||USD||Sep 2007|
|0W10||LSE (London Stock Exchange)||Yes||Common Stock||GB||EUR||Sep 2007|
MagForce AG operates in the field of nanotechnology-based cancer treatment in Germany and Poland. It offers NanoTherm therapy for the treatment of solid tumors; NanoTherm, a ferrofluid liquid containing superparamagnetic iron oxide nano-particles that can be activated in an alternative magnetic field; NanoPlan, a therapy planning software; and NanoActivator, a magnetic field applicator. The company was founded in 1997 and is headquartered in Berlin, Germany.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/04/10 00:10|
|End of Day Share Price||2020/03/24 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.